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INTRODUCTION
Depression has been recognized as the most frequent psy-
chological symptom in chronic dialysis patients (1). It has
been also known to relate to the severity, healing, and recov-
ering process and mortality among patients with end-stage
renal disease (ESRD) who are treated with hemodialysis (HD)
(1). The incident rate of depression in ESRD has been report-
ed from 10% to 100%. Several explanations for this wide range
of the incidence rate have been addressed: First, it is difficult
to discriminate the depressive symptoms from the uremic
symptoms; second, depending on the methods and subjects,
the incidence rate might be variable (2-5). Several losses such
as loss of renal function, loss of role in the workplace and fam-
ily, and loss of sexual function account for the high incidence
rate of depression in ESRD patients. It has been also report-
ed that ESRD patients continue to experience a decrease in
quality of life (6). The stress is maximized that they have to
rely on others (doctors or family) or machines, which wors-
ens the depression (7-9).
Recent studies have suggested that the alterations of cyto-
kines in HD might be related to depression and altered levels
of serum albumin and cholesterol (10-13). It has also been
reported that acute phase, pro-inflammatory cytokines (14)
such as interleukin 1 (IL-1), interleukin 6 (IL-6) and C-reac-
tive protein (CRP) are activated in long-term HD patients
(15). Experimental and clinical studies have indicated that
these cytokines secreted excessively by stress might be one
of the reasons for depression (16, 17). It has been known that
these cytokines trigger catabolism of the body protein, which
results in a negative nitrogen balance that induces malnutri-
tion and decrease of appetite (15). 
Malnutrition has been considered to relate closely to mor-
bidity, mortality, decrease in quality of life, and delayed recov-
ery in ESRD patients (1, 18). In consideration of the high
incidence rate of depression among patients with HD, the
causal relationship between depression and malnutrition
among them needs to be explored (9).
Kimmel et al. (1) speculated that depression influences
the immunological factors, nutritional status, and treatment
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The Effects of Antidepressant Treatment on Serum Cytokines and
Nutritional Status in Hemodialysis Patients
The aim of this study was to investigate the effects of antidepressant treatment on
serum cytokines and nutritional status in hemodialysis patients. Twenty-eight hemo-
dialysis patients with a depressed mood were given 20 mg of fluoxetine for 8 weeks.
The degree of depressive symptoms, the serum levels of interleukin-1 , interleukin-
2, interleukin-6, tumor necrosis factor- , c-reactive protein, and markers of nutritional
status were assessed at baseline and after treatment. The outcome was assessed
in terms of response to treatment (>50% reduction in the score of the Hamilton depres-
sion rating scale). Antidepressant treatment decreased the serum level of interleukin-
1 in both response and nonresponse groups, and increased the serum level of
interleukin-6 only in the response group. At baseline, the level of interleukin-6 in the
response group was lower than in the nonresponse group. Antidepressant treatment
also increased fat distribution significantly in the response group which might have
slightly improved the nutritional status. This study suggests that antidepressant treat-
ment improve depressive symptoms and may affect immunological functions and
nutritional status in chronic hemodialysis patients with depression.
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compliance. These factors can influence the survival rate of
the patients, duration of hospitalization, and quality of life.
Studies have also shown that although psychiatric treatments
such as antidepressant and group therapy are effective to deal
with depression and malnutrition, it is difficult to tell whether
the improvement results only from these treatments or from
interactions with other factors. Although the mechanisms of
the effects of depression on survival are poorly understood, it
is reasonable to hypothesize that the psychiatric treatments
might improve the survival rate of the patients.
In this respect, we aimed to explore the effects of antide-
pressant treatment on serum cytokines and nutritional status
in hemodialysis patients. 
MATERIALS AND METHODS
Subjects
Forty-three patients with ESRD on HD were selected for
this study. The study took place at the outpatient HD unit
of Hallym University Hospital (Chunchon, Korea). Data from
the subjects were collected from January 1 to June 30, 2001.
Some patients were excluded because they could not complete
the self-rating scale for disturbance of cognitive function.
Patients were also excluded if they had experienced acute in-
flammation state for at least two weeks prior to the study, if
they had been alcohol dependent, if they have autoimmune
disease, or if they had experienced recent poor appetite and
weight loss. In addition, because this study used antidepres-
sant treatment, patients who scored less than 11 in the Beck’s
depression rating scale (BDI) (19) and less than 7 in the Hamil-
ton depression rating scale (HAMD)(20) were excluded as well.
Assessment of depression
The 17-item Hamilton depression scale was administered
before and after eight weeks of antidepressant treatment. We
measured clinical improvement as a percent of change in HA-
MD score, response to treatment (defined as a ≥50% reduc-
tion in the score from baseline to eight weeks treatment). The
subjects were divided into two groups: Response Group (RP)
and Nonresponse Group (NR) that showed a less than 50%
decreased rate (21).
Hemodialysis and antidepressant treatment
All of the HD subjects were treated using polymethylme-
thacrylate dialyzer. During the period of this study, the fre-
quency and session length of dialysis and dry weight were
maintained equally. After breakfast, the subjects took one dose
of antidepressants (20 mg fluoxetine) in addition to the same
amount of medications as before the experiment. 
Laboratory test and measurement of cytokines
Before and after eight weeks of antidepressant treatment,
15 mL of blood was taken immediately after initiation of HD.
The serum was separated and kept at -70℃. Interleukin-1
beta (IL-1 ), interleukin-2 (IL-2), interleukin-6 (IL-6) and
tumor necrosis factor-alpha (TNF- ) were measured by ELISA
kit from Biosource Europe SA (Belgium) using a Cobra Gam-
ma Counter (Packard, IL, U.S.A.). 
Index of nutrition status
Before and after eight weeks of antidepressant treatment, a
bio-electrical impedance analyzer (BIA) (Inbody 2.0, Biospace,
Korea) was used to measure body weight, fat-free mass, total
body water, body fat mass, fat distribution, body mass index,
and arm muscle circumference.
Statistical analysis
Chi-square test and independent t-test were conducted to
compare variables between the RP group and the NR group.
A paired t-test was used to compare values obtained before
and after antidepressant treatment. A statistical software pro-
gram (SPSS for Windows version 10.0; SPSS Inc, Chicago,
IL) was used to do the statistical analysis. The level of signifi-
cance was set to be less than 0.05. 
RESULTS
Four subjects were excluded from the analysis because they
had lower scores of BDI (less than 11) and HAMD (less than
7). Four subjects with a poor medication compliance, three
subjects who had transferred to other hospitals, one subject
who had stopped HD because of renal transplantation, and
three subjects who had died were excluded additionally. There-
fore, 28 subjects were included in the analysis.
Demographic characteristics
The study subjects were 15 male and 13 female patients.
The average age of the subjects was 43.6±11.3 yr. In terms
of their economic status measured by annual income, 23 had
a salary of less than US $10,000 per year, 4 had a salary between
US $10,000 and US $30,000, and one subject earned more
than US $30,000. Nineteen subjects were married, three re-
mained single and three were divorced. The average duration
of education was 10±3.5 yr. The total duration of hemodialysis
was 64.4±38.5 months (range, 12 months to 156 months).
As for drinking, 25 subjects stated that they did not drink
and three subjects stated that they drank more than three to
five times a month. All subjects responded that they did not
smoke. There were no statistically significant differences in demo-386 S.-K. Lee, H.-S. Lee, T.-B. Lee, et al.
graphic characteristics between the RP group and the NR
group (Table 1).
The degree of depression (Table 2)
There was no statistically significant difference in the base-
line HAMD scores between the RP group and the NR group.
The antidepressant treatment significantly decreased the HA-
MD scores in the RP group (15.36±1.75 vs. 6.36±1.22,
p<0.05). 
The serum cytokines (Table 2)
The levels of IL-2, TNF- , and CRP were not significantly
different before and after the antidepressant treatment in both
NR and RP groups. Antidepressant treatment significantly
decreased the IL-1 level in both groups (18.87±2.1 vs.
10.52±1.18, p<0.05). However, the level of IL-6 was sig-
nificantly increased only in the RP group (1.66±1.66 vs.
8.85±3.39, p<0.05). The baseline level of IL-6 in the RP
group was significantly lower in the RP group as compared
to NR group (1.66±1.66 vs. 10.88±3.78, p<0.05). 
Nutritional status (Table 2)
After eight weeks of antidepressant treatment, there was
no significant difference in body weight and total body water
between the two groups. However fat distribution was sig-
nificantly increased in the RP group (0.815±0.012 vs. 0.823
±0.012, p<0.05). 
DISCUSSION
The incidence rate of depression in chronic HD patients is
10-100% (1-5). In this study, 90% of the total subjects (39
subjects in 43 subjects) revealed mild depression or more severe
symptoms. One reason for the high rate of depression was the
use of the BDI self-rating scale. The low cut-off points (11
points for BDI and 7 points for HAMD) also contributed to
the higher depression rate in this study.
Recently, selective serotonin reuptake inhibitors (SSRI) have
been widely used for depression in HD patients (22, 23). Espe-
cially, fluoxetine, which is a selective serotonin reuptake inhi-
bitor, has a little anticholinergic effect and is excreted mainly
Values are expressed as mean±SE. 
*Low means below US $10,000 of annual income.
Response group 
(n=11)
Nonresponse group
(n=17)
Age (yr) 42.73±3.34 44.24±2.83
Male (%) 45 65
Living with partner (%) 66 71
Economic status (low %)* 81 82
Education (yr) 10.30±1.23 9.76±0.82
Hemodialysis duration  61.27±9.70 66.35±10.40
(months)
Table 1. The comparison of demographic data between respon-
se group and nonresponse group after antidepressant treatment
(n=28)
Total (n=28)
Baseline 8 Weeks
Severity of depression
BDI 14.7±1.4 16.5±2.2 13.6±1.9
HAMD 13.54±0.99 10.07±1.22* 15.36±1.75 6.36±1.22* 12.35±1.12 13.54±1.85
Cytokines
IL-1 (pg/mL) 18.87±2.1 10.52±1.18* 16.20±2.55 7.69±1.48* 22.09±2.94 13.30±1.41*
IL-2 (pg/mL) 0.57±0.04 0.72±0.12 0.52±0.06 0.57±0.08 0.60±0.05 0.82±0.19
IL-6 (pg/mL) 7.26±2.51 10.58±2.37* 1.66±1.66
� 8.85±3.39* 10.88±3.78 11.70±3.27
TNF- (pg/mL) 80.67±11.4 65.37±5.97 53.15±4.67 46.60±2.88 96.45±6.88 76.39±8.30
CRP (mg/mL) 2.19±0.5 2.34±0.6 1.62±0.53 2.26±0.52 2.56±0.75 3.04±0.91
Nutritional status
Body weight (kg) 54.74±2.08 54.92±1.98 50.71±2.35 50.61±2.33 57.64±2.97 57.99±2.73
Fat free mass (kg) 44.60±1.51 45.06±1.39 44.18±2.66 44.70±2.65 44.92±1.80 45.35±1.46
Total body water (L) 31.13±1.0 31.17±0.98 30.58±1.86 30.91±1.85 31.56±1.08 31.38±1.03
Body fat mass (kg) 10.75±1.46 10.45±1.42 8.00±0.88 7.37±1.83 12.72±2.32 12.64±2.20
Fat distribution (kg) 0.85±0.013 0.84±0.012 0.815±0.012 0.823±0.012* 0.863±0.019 0.865±0.020
Body mass index (kg/m
2) 21.52±0.74 21.40±0.69 20.94±1.09 20.85±1.03 21.99±1.02 21.83±0.95
Arm muscle  22.16±0.44 22.33±0.40 21.86±0.74 22.16±0.70 22.40±0.55 22.46±0.48
Circumference (cm)
Table 2. The comparison of severity of depression, cytokines level and nutritional status between the response group and the nonre-
sponse group after antidepressant treatment (n=28)
Response group (n=11)
Baseline 8 Weeks
Nonresponse group (n=17)
Baseline 8 Weeks
Values are expressed as mean±SE. BDI, Beck’s depression rating scale; HAMD, Hamilton depression rating scale.
*p<0.05 versus baseline values (paired t-test), 
� p<0.05 versus baseline values in the nonresponse group (independent t-test).Effects of Antidepressant on Cytokines 387
by the liver. There is no influence of renal dysfunction, the
rate of elimination, volume of distribution, or protein binding
of fluoxetine. The plasma concentration of fluoxetine and nor-
fluoxetine metabolites were not significantly changed by the
process of hemodialysis (23). 
The recommended dose of fluoxetine is 20-40 mg in the
depressed patients (24). Surman (25) stated that in consider-
ation of side effects among HD patients, two thirds of the
amount for major depression is proper to HD patients. In this
study, 20 mg of fluoxetine were used for the treatment of
depressive symptoms. No patient showed side effects of med-
ication. However, it was not clear whether the amount of 20
mg was enough to improve depression for all subjects.
It has been suggested that IL-1 , TNF- , and IL-6 are
pro-inflammatory cytokines, which are mainly secreted from
monocytes, and function as major etiological factors of hemo-
dialysis-related inflammatory responses (14). The blood levels
of IL-1 and TNF- were higher among HD patients than
among control patients (26, 27), and these over-secretion of
cytokines have been observed in amyloidosis (28), malnutri-
tion (29, 30), and atherogenesis (31, 32). Cytokines may be
secreted inappropriately due to frequent contact with bioin-
compatible dialyzer and uremia itself. And a correlation be-
tween over-secreted cytokines in HD patients and their depres-
sive symptoms has also been suggested. Some studies have
supported the possibility that cytokines can be overly secreted
by stress and the over-secreted cytokiness can trigger depres-
sion (16). Other studies have shown that over-secreted pro-
inflammatory cytokines can cause depression (33, 34). It has
recently been suggested that antidepressants decrease the
secretion of pro-inflammatory cytokines such as IL-1 , IL-2,
and TNF- and have negative immunoregulatory effects (35).
This study showed that after eight weeks of antidepressant
treatment, while the level of IL-1 decreased significantly
among all subjects, IL-6 increased significantly only in the
RP group. Previous studies reported that after antidepressant
treatment, IL-6 has decreased (36), however, some studies
showed that after four weeks of antidepressant treatment using
fluoxetine, IL-6 was significantly increased (35). The IL-6 has
been considered as a cytokine with both pro- and anti-inflam-
matory effects. Therefore, it has been called a highly pleiotropic
cytokine (37), functioning as a mediator to control secretion
of other cytokines from monocytes (38). Schindler et al. (39)
stated that IL-6 controls secretion of IL-1 and TNF- . And
it has been suggested that the gene expression of IL-6 is st-
rongly controlled by cortisol, which decreases IL-6 (40-42).
One of possible hypotheses from this study is as follows: Stress
in HD patients activates the HPA axis to increase cortisol.
While the increased cortisol keeps IL-6 at a lower level, sta-
bilization of the HPA axis by antidepressant treatment will
decrease the cortisol level, and after then these changes may
increase IL-6 level paradoxically.
However, it has been suggested that there was no reverse
correlation between cortisol and cytokines among endogenous-
ly depressed patients (43, 44). In this study, because the sub-
jects were HD patients who had been exposed to stress for a
while, they were different from endogenously depressed pati-
ents. Therefore, the results of this study might differ from
those of studies involving endogenously depressed patients.
This was supported by result from this study that at the early
stage of treatment, the serum level of IL-6 in the RP group
was significantly lower in the NR group. This result was
consistent with the result from the study by Maes et al. (33),
which showed that IL-6 was significantly high among patients
who resisted antidepressant treatment. It has also been recently
reported that while the level of IL-1 did not change among
patients with atypical depressions, it changes in those with
typical depression (45). These results suggest that the immu-
nological pathophysiology and types of mechanism of antidepres-
sants can be different depending on the subtype of depression
(44).
Malnutrition in HD can be caused by a poor appetite, insuf-
ficient food intake, depressive symptoms, intake of various
medication, bio-incompatible dialyzer, disturbance of com-
pensating mechanisms for protein metabolism, and increased
protein catabolism (46, 47). Because the malnutrition is related
to morbidity and mortality (48), regular assessment of the
nutritional status of the HD patient is very important.
Measurement of skinfold thickness, mid arm muscle cir-
cumference, dual energy radiograghy absorptiometry, and BIA
have been suggested as methods to assess nutritional status.
However, controversies exist on the precise index of measure-
ment (49). For instance, because HD patients experience a
severe change of the amount of Total Body Water measured
by the method, BIA has been suggested to be an inaccurate
index of measurement. In this study, even though BIA has
been used to assess the nutritional status after the antidepres-
sant treatment in all subjects, a significant change of TBW
was not observed. Therefore, the comparison of nutritional
status before and after the treatment was appropriate. Changes
in dialysis adequacy can also influence the nutrition status.
In this study, however, the influence of dialysis’ change on the
nutrition status was controlled by keeping the dose of dialysis
constant. 
Depression among HD patients can cause biological changes
in the nutritional status, and the immune system, and de-
creased compliance to treatment. These changes can result in
poorer prognosis of the disease and mortality (1). The corre-
lation between depression and malnutrition has been report-
ed (9). It has been stated that after antidepressant treatment,
intracellular fluid, which was measured by BIA, and the am-
ount of fat-free mass increased (50). In this study, the nutri-
tion indices such as fat-free mass, fat distribution, and arm
muscle circumference all increased in the RP group. The fat-
free fat mass was calculated by combining total body water,
protein, and mineral. Therefore, an increase in fat-free mass
is proportional to increase of protein and mineral when total
body water is not changed. Increased waist hip ratio and arm388 S.-K. Lee, H.-S. Lee, T.-B. Lee, et al.
muscle circumference which is related to anabolism, also indi-
cate improvement of nutrition (9). Among the NR group,
the indices of nutrition did not improved. These results indi-
cate that among HD patients, depression is related to nutri-
tion, and antidepressant treatment can improve the nutrition-
al status.
This study has a couple of limitations. The number of the
subjects was relatively small, and a placebo-controlled study
was not conducted. In addition, because the dosage of the
antidepressant was fixed for all subjects, the amount of antide-
pressant treatment might not be enough to investigate opti-
mally the treatment effects of depression. 
Considering these limitations, we need further studies on
the relationship between depression and ESRD, and the role
of cytokines and the hypothalamus-pituitary-adrenal axis in
the pathogenesis of malnutrition in patients with chronic renal
disease.
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